Trial Leadership and Female Enrollment

Does investigator sex predict how many women are enrolled in a trial?

Research on trial leadership and investigator sex shows a real but uneven pattern: sites led by women tend to enroll more women, yet the effect size varies by specialty and study design, and no single factor fully explains enrollment gaps.

A 2025 site-level analysis of multicenter vascular trials found that investigator sex predicted female enrollment rates at the site level — sites with female principal investigators enrolled a higher proportion of women than sites with male principal investigators. The association held after adjusting for site size and trial type. The authors describe this as a correlation, not a proven cause-and-effect chain, and the study covered vascular surgery specifically, so the finding may not transfer to peptide medicine trials.

Oral and maxillofacial surgery tells a parallel story. A gender disparities in research leadership analysis found women held a small minority of principal investigator roles — which the authors connect to downstream gaps in who gets studied. Fewer women leading trials means fewer women designing inclusion criteria, recruiting participants, or noticing when dropout patterns differ by sex.

Investigator sex is one piece of a larger puzzle. A qualitative study of women of color found that distrust, scheduling barriers, and feeling unseen by research teams shaped nonparticipation far more than who signed the protocol. Women in that study described wanting to be heard, not just counted. Investigator demographics matter, but so does the entire research environment a participant walks into.

What the current evidence shows and does not show:

• Sites with female investigators enrolled more women in vascular trial data, but the absolute difference and its clinical meaning are still being worked out.
• PTSD trial enrollment research found that disease-specific factors — not just investigator characteristics — predicted sex-based enrollment patterns. No single lever fixes representation.
• Hypertension and diabetes trial reviews show women remain underrepresented even in conditions where they carry a substantial share of disease burden, regardless of who leads the trial.

Investigator sex appears to matter. The evidence is real. It is also incomplete. Representation in trial leadership is one variable among many — structural, cultural, and logistical — that shape whether women in any given study reflect the people who will eventually use the medicine.

This content is for general health education only and is not medical advice. Consult a qualified healthcare provider about your individual situation.

Why do women of color decline trials even when they feel heard by their care team?

Women of color decline trials even when they feel heard because structural barriers — not the care relationship alone — drive the decision. PMID 42635329 found that women in this study named trust in their individual clinician as separate from trust in the trial system itself; feeling heard by a doctor did not resolve concerns about who holds trial leadership, who designed the study, and whose interests shaped the research questions.

That distinction matters. A warm exam room conversation cannot undo decades of documented exclusion at the institutional level. PMID 42635329 identified several specific, recurring reasons women of color gave for declining participation even after reporting positive relationships with their care teams:

Distrust of institutions, not individuals. Women in this study separated their personal clinician from the sponsoring organization, hospital system, or pharmaceutical company running the trial. Comfort with one did not transfer to the other.

Perceived irrelevance of the research question. Women in this study questioned whether the trial was designed with their health priorities in mind, or whether they were being recruited to fill a diversity quota without the science reflecting their needs.

Logistical load falling on caregivers. Trial participation often requires multiple visits, time off work, and childcare — costs that fall unevenly on women who are already primary caregivers.

Lack of representation in trial leadership. PMID 42635329 and PMID 42362425 both document that women, and women of color specifically, are underrepresented among principal investigators and trial leadership teams. Women in these studies named visible leadership diversity as a signal they used to judge whether a trial was designed for people like them.

Fear of being a "last resort" subject. Some women in this study expressed concern that they were being approached because the trial had failed to recruit enough participants, not because researchers genuinely wanted their data.

PMID 42465047 adds context: even at Federally Qualified Health Centers — settings that specifically serve historically underserved populations — enrollment of women and minority groups in hypertension and diabetes trials remained lower than their share of the disease burden. Presence in a trusted clinical setting did not close the gap.

Better bedside manner alone will not increase trial participation among women of color. The gap between feeling heard and choosing to enroll reflects a rational response to a research system that has historically collected data from these women without returning proportionate benefit.

This section is for general health education only and does not constitute medical advice. Speak with a licensed clinician about decisions specific to your health.

How does trial design affect sex enrollment in PTSD research?

Trial design choices shape sex enrollment in PTSD research in measurable, documented ways — and trial leadership decisions sit at the center of that pattern. A 2025 analysis of PTSD randomized clinical trials found that specific design features predicted whether women enrolled in meaningful numbers, or were effectively screened out before a study even began (PMID 42628151).

Several design features consistently reduced female enrollment in the PTSD trials that researchers examined:

• Veteran-focused recruitment sites. Because the U.S. veteran population skews male, trials anchored to VA settings drew fewer women by default.
• Combat-trauma inclusion criteria. Eligibility language specifying combat exposure excluded many women whose PTSD followed sexual assault, childhood trauma, or other non-combat events.
• Exclusion of comorbid conditions. Women in this study were more likely than men to carry co-occurring depression or anxiety diagnoses. Trials that excluded those conditions removed a disproportionate share of eligible women.
• Narrow age windows. Criteria that excluded older adults cut into a life stage where women's PTSD prevalence remains high.

The same research noted that trials with broader trauma-type eligibility and community-based recruitment sites enrolled women at higher rates — a concrete, fixable difference in how a protocol gets written (PMID 42628151).

Who runs a trial matters. Research on multicenter vascular trials found that sites with female principal investigators enrolled women at higher rates than sites led by male investigators (PMID 42702651). A separate analysis of oral and maxillofacial surgery trials documented that women held a minority of lead investigator roles, a gap the authors linked to downstream enrollment and generalizability problems (PMID 42362425).

Structural barriers compound design gaps. Women of color reported in one qualitative study that distrust, scheduling conflicts, and lack of culturally specific outreach drove their decisions not to participate — factors that protocol writers control, at least in part (PMID 42635329).

When a PTSD trial reports its results, check the enrollment table. If women made up a small fraction of participants, the trial did not establish whether those findings apply to women with different trauma histories, comorbidities, or life stages. That gap belongs to the study design, not to the women who weren't there.

This content is for general health education only and is not medical advice. Consult a qualified clinician before making any treatment decisions.

Are women underrepresented in hypertension and diabetes trials at community health centers?

Yes and no — women are underrepresented in hypertension and diabetes trials at community health centers, but the picture is more complicated than a simple gap. A 2025 systematic review and meta-analysis examined clinical trial leadership and enrollment patterns at Federally Qualified Health Centers (FQHCs) — community clinics that serve patients regardless of ability to pay — and found that women made up a majority of participants in some disease categories while remaining underrepresented in others, depending on the condition studied and how researchers defined "underrepresentation."

What the FQHC review found

The systematic review analyzed hypertension and diabetes trials conducted at FQHCs. Women in this study were enrolled at rates that did not consistently match their share of the disease burden in the communities these centers serve. Enrollment gaps were not uniform — they varied by condition, trial design, and the demographic makeup of each site's patient population.

Historically underserved populations, including women of color, faced compounding barriers to participation. A separate qualitative study on clinical trial nonparticipation among women of color identified concrete reasons women declined or were never offered enrollment: distrust of research institutions, scheduling conflicts, lack of transportation, and inadequate childcare. These were not reflections of disinterest in their own health.

Why this matters for interpreting peptide research

Peptide medicines that target metabolic pathways — including those studied for blood pressure or blood sugar regulation — are tested in trial populations. When women in those trials are not representative of the people who will eventually use the medicine, the resulting data on effectiveness and side effects may not apply evenly across all patients. The trial did not establish how results translate to groups who were underenrolled.

A 2025 FDA-drug analysis covering approvals from 2015 to 2023 found that sex representation in trials varied significantly by disease indication — some therapeutic areas had near-parity while others did not, and the gap tracked with which conditions researchers historically prioritized.

What remains unknown

Researchers have not yet established whether enrollment gaps at FQHCs produce measurable differences in how well approved treatments work for women who receive care at those sites. The FQHC review called for standardized reporting of sex, race, and ethnicity in trial publications. Many studies in its sample did not report these variables consistently, which makes comparison across trials difficult.

This is not a reason to avoid treatment. Ask your clinician what the trial population looked like and whether your own health profile was represented.

This section is for general health education only and does not constitute medical advice. Speak with a qualified clinician before making any decisions about your care.

Does the sex of trial leadership vary by surgical specialty?

Yes, the sex of trial leadership does vary by surgical specialty — and oral and maxillofacial surgery is one of the most documented examples of that gap. A 2025 analysis found that women held a minority of principal investigator roles in oral and maxillofacial surgery trials, a pattern that mirrors broader surgical fields where women remain underrepresented in senior research positions.

Trial leadership shapes which questions get asked, which populations get enrolled, and which outcomes get measured. When the sex of trial leadership skews heavily male in a specialty, the research questions that drive that field tend to reflect male-typical presentations — and that can leave gaps in what we know about how treatments work across different bodies.

The oral and maxillofacial surgery study examined gender disparities in research trial leadership within that one specialty, so its findings apply there, not to surgery as a whole. Extrapolating to other specialties — orthopedics, cardiothoracic, vascular — requires separate evidence.

Vascular surgery offers a related data point. A site-level analysis of multicenter vascular trials found that investigator gender at the site level was associated with female enrollment rates: sites led by women tended to enroll more women. That is a site-level pattern, not a universal rule, and the study did not establish causation.

Whether these leadership gaps produce measurable differences in peptide-specific trial design or outcomes remains unknown. The connection is plausible but unproven. Most surgical fields have not published the kind of systematic audit that oral and maxillofacial surgery now has.

When you read a peptide trial, check three things: who led the study, which specialty it sits in, and whether enrollment numbers for women in that study are reported. Those questions will tell you more than the headline results alone.

This section is for general health education only and does not constitute medical advice. Consult a qualified healthcare provider before making any decisions about treatment.